Navigation Links
Juventas Therapeutics Initiating Phase II Clinical Trial of JVS-100 for Treatment of Critical Limb Ischemia
Date:1/3/2011

CLEVELAND, Jan. 3, 2011 /PRNewswire/ -- Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).  JVS-100 encodes Stromal-cell Derived Factor 1 (SDF-1), which has been shown in several pre-clinical studies to promote tissue repair through activation of natural stem-cell repair pathways, promotion of new blood vessel formation and prevention of on-going cell death.  The new trial builds on the JVS-100 cardiovascular program that includes a U.S. Phase I heart failure (HF) clinical trial for which the Company recently completed enrollment of 17 patients.

"Juventas is excited to extend its clinical pipeline to include treatment of patients with CLI," stated Rahul Aras, Ph.D., President & CEO for Juventas Therapeutics.  "With our heart failure and critical limb ischemia programs moving into mid-stage clinical trials, the Company is focused on leveraging its regenerative medicine platform to address a range of cardiovascular indications with the goal of providing novel therapies to patients with limited options."

The randomized, placebo-controlled study will evaluate the efficacy and safety of JVS-100 in 48 patients (36 JVS-100 treated; 12 placebo) with Rutherford Class IV or V CLI.  The clinical trial will measure several efficacy endpoints including time to amputation, transcutaneous oximetry (TcPO2), Ankle-Brachial Index (ABI) and ulcer closure.  

"Critical limb ischemia is a devastating disease for which there is currently no FDA-approved drug for treatment," said Douglas Losordo, M.D., Principal Investigator for the trial and Director of the Feinberg Cardiovascular Research Institute at the Northwestern University Feinberg S
'/>"/>

SOURCE Juventas Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Zenobia Therapeutics, Inc. Enters Into a Research Collaboration With Lundbeck for the Parkinsons Disease Target LRRK2
2. Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy
3. Talecris Biotherapeutics Announces Jury Verdict in Contract Dispute
4. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
5. Reportlinker Adds Global Bladder Cancer Therapeutics Industry
6. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
7. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
8. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
10. NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 According to Jeff Howell, ... of ITRA Global, new development in Downtown Toronto is ... council approving another 755 storeys of new development last ... cranes will be dominating the Toronto skyline for the ... an unquenchable thirst for new development. , As the ...
(Date:9/15/2014)... 15, 2014 EnGeneIC, Ltd. , ... treatment of cancer through the targeted delivery of ... together with the Asbestos Disease Research Institute (ADRI), ... South Wales (NSW) Premier,s Award for Excellence in ... the hospitals that will be involved in the ...
(Date:9/15/2014)... Northeastern University has developed a novel method for ... of nanocarbon structures in carbon nanotube arrays. The ... allow the researchers to tailor the physical properties ... from electronic devices to CNT-reinforced composite materials found ... Their findings were published in the journal ...
(Date:9/15/2014)... The chemistry, taste, and health effects of tea ... published by the nonprofit American Botanical Council (ABC). Recent research ... its effects on the phytochemical compounds in tea ( Camellia ... Dr. Ahmed in the Yunnan province ... for the future of medicinal botanicals. Dr. Ahmed,s report ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4
... 7 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon" or the ... receipt of preliminary proxies, the Company believes that it has ... ("Merger") by and among Dragon, Chief Respect Limited, Datong Investment ... Yanlin Han . The Merger must be approved by holders ...
... , , ... a 25 percent replacement for petroleum oil more than doubles rubber,s stretchability and reduces its environmental ... Ford,s ... automotive parts such as deflector shields and baffles, radiator deflector shields, cupholder inserts and floor mats ...
... DATATRAK International, Inc. (OTCQX: DATA), a technology and services ... industry, today announced that it privately placed 357,857 common shares ... with certain members of its Board of Directors and management ... are restricted securities and are subject to the restrictions on ...
Cached Biology Technology:Dragon Pharma announces receipt of preliminary proxies to approve merger 2Dragon Pharma announces receipt of preliminary proxies to approve merger 3Ford Pioneers Patent-Pending Use of Eco-Friendly Soy Oil in Rubber Automotive Parts 2Ford Pioneers Patent-Pending Use of Eco-Friendly Soy Oil in Rubber Automotive Parts 3Ford Pioneers Patent-Pending Use of Eco-Friendly Soy Oil in Rubber Automotive Parts 4DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 2DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management 3
(Date:9/15/2014)... Earth for the first 500 million years after it ... day, complete with oceans, continents and active crustal plates. ... called the Hadean, has gained substantial new support from ... more than 4 billion years ago with those formed ... possible geological analog for early Earth. , The study ...
(Date:9/15/2014)... cognitive function may play roles in one,s musical aptitude, ... timbre, tone durations, and formal structure in music. , ... that extremes in musical aptitude (extreme capacity/no capacity) are ... having moderate aptitude. , "This is a typical feature ... and it is influenced to varying degrees by environmental ...
(Date:9/15/2014)... from GEOMAR Helmholtz Centre for Ocean Research Kiel ... demonstrated for the first time, that the single ... Emiliania huxleyi , can adapt simultaneously to ... study, the researchers found no evidence for the ... aspects of climate change would interfere with each ...
Breaking Biology News(10 mins):Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3Small algae with great potential 2Small algae with great potential 3
... 2013) As public health authorities across the globe grapple ... of Medicine microbiologists and colleagues have identified the unique resistance ... resistant to carbapenems. Carbapenems are a class of antibiotics ... bacteria, including E. coli and Klebsiella pneumonia ...
... of poultry could be improved by a discovery about how ... chicken,s genetic make-up can affect the signals sent from its ... has had enough to eat. Poultry farmers often have ... to feelings of fullness and can overeat, affecting their ability ...
... , March 26, 2013 Today, Hyland ... Intelligence Corporation (CIC; OTCQB: CICI), a leading ... help organizations automate processes, such as electronic mortgage ... enterprise content management (ECM) solution, OnBase, with ...
Cached Biology News:New study identifies unique mechanisms of antibiotic resistance 2Appetite genes are key to better diets for poultry, study shows 2Hyland Software Partners with Communication Intelligence Corporation (CIC), a Leading Supplier of Electronic Signature Solutions 2Hyland Software Partners with Communication Intelligence Corporation (CIC), a Leading Supplier of Electronic Signature Solutions 3